NCT05551936 2026-02-17
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting
Clinical Trials
7 trialsNCT06575686 2026-01-21
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
City of Hope Medical Center
Phase 2 Suspended
NCT05934838 2025-08-15
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Weill Medical College of Cornell University
Phase 1 Recruiting
NCT05994235 2025-04-09
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT05618366 2025-04-08
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Weill Medical College of Cornell University
Phase 1 Recruiting
NCT05604417 2023-07-07
Zandelisib + Tazemetostat in R/R Follicular Lymphoma
Massachusetts General Hospital
Phase 1/2 Withdrawn
NCT05152459 2023-05-31
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
City of Hope Medical Center
Phase 1/2 Withdrawn